Investors Warned: Class Action Opportunity for PROCEPT BioRobotics Losses

Alert for Investors in PROCEPT BioRobotics Corporation

In the realm of securities law, recent developments have stirred considerable attention regarding PROCEPT BioRobotics Corporation (NASDAQ: PRCT). Investors have been alerted by the national shareholder rights firm Hagens Berman Sobol Shapiro LLP about the opportunity to join a class action lawsuit. This lawsuit seeks to address the substantial financial losses incurred by investors due to alleged deceptive practices surrounding the company’s sales of its proprietary product, the single-use handpiece used in Aquablation therapy for treating enlarged prostates.

Background of the Allegations

The class action suit focuses on the time period between February 28, 2024, and February 25, 2026. Allegations arose following a series of disappointing financial results that highlighted significant underperformance in handpiece unit sales. According to reports, the firm's extensive discount program led to inflated sales figures, as customers were encouraged to order supplies exceeding their actual demand, thus manipulating the sales metrics.

Specifically, the lawsuit claims that investors were kept in the dark regarding the true condition of PROCEPT's inventory levels and sales strategies. As a result, the firm may have breached federal securities laws, which require transparent and truthful communications to investors. This alleged lack of disclosure prevented investors from accurately assessing the health of PROCEPT’s business, resulting in significant financial losses.

Revealing Conduct and Market Reaction

The series of disclosures started with a disappointing announcement on August 6, 2025, when the company revealed a dramatic decline in handpiece sales, missing market expectations. This concern continued throughout the third and fourth quarters of 2025, culminating in alarming revelations about inventory levels that were not disclosed to investors.

During a conference call, management admitted to not properly managing customer inventories and revealed that excess handpiece stocks were inflating sales numbers. Such information, if disclosed earlier, might have altered investor behavior and stock valuations significantly. Following these disclosures, the price of PROCEPT shares tumbled over 48%, decreasing by $22.06 from August 6, 2025, to February 25, 2026.

Legal Redress and Encouragement for Investors

As this situation unfolds, Hagens Berman has extended an invitation to all investors who have experienced substantial losses related to their PROCEPT investments to come forward. They are encouraged to share their experiences and participate in this class action lawsuit to seek potential compensation. The firm is particularly interested in speaking to those who might have information that could assist the ongoing investigation.

Seeking Justice

In addition to helping investors recover damages, this case seeks to uphold accountability in corporate governance and transparency in financial reporting. Reed Kathrein, a partner at Hagens Berman leading this investigation, stated, "We're examining whether PROCEPT intentionally pulled sales forward to mask operational difficulties and whether they communicated transparently with their investors."

For anyone who invested in PROCEPT and believes they qualify as a participant in this legal action, Hagens Berman advises reaching out either through their website or via phone.

If you have non-public information about PROCEPT, the SEC Whistleblower program could provide a secure route for disclosure, possibly allowing for financial rewards based on any successful recovery made by the SEC.

This situation underlines the importance of investor vigilance and corporate accountability, as investors seek transparency and justice in light of these recent allegations.

In the complex world of securities, remaining informed and proactive can make a significant difference for investors navigating such tumultuous waters. Hagens Berman offers not just legal representation, but a fuller pursuit of accountability for corporate negligence that impacts many lives across the investing spectrum.